pCPA Activity Overview
| Status | Total Negotiations | Summary |
|---|---|---|
| Active Negotiations | 30 | Non-oncology: 16 Oncology: 14 |
| Under Consideration for Negotiation | 20 | Non-oncology: 9 Oncology: 11 |
| Completed Negotiations | 888 | With Letter of Intent: 768 Without agreement: 120 |
| Negotiations That Were Not Pursued | 114 |
pCPA activity in the last four weeks
Activity for the last four weeks. Please note that these updates may take one to two weeks to be processed.
Engagement letters issued in the last four weeks
| Brand Name | Manufacturer | Indication | Engagement Date |
|---|---|---|---|
| Upgolyv | Jamp Pharma Corporation | for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis and ulcerative colitis | |
| Talzenna | Pfizer Canada ULC | In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC). | |
| Movantik | Knight Therapeutics Inc. | Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s). | |
| Opdivo-Yervoy | Bristol Myers Squibb Canada Inc. | For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC). |